Valvular & structural heart disease
A streamlined pathway for transcatheter aortic valve implantation: the BENCHMARK study
Authors' conclusion
Broad implementation of BENCHMARK practices contributes to improving efficiency of TAVI pathway reducing LoS and costs without compromising patient safety.
Study context
- Population
- Patients with severe symptomatic aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) with balloon-expandable valves, 2020–2023
- Participants
- 1,491 vs 897
- Comparison
- After vs before implementation of BENCHMARK best practices
- Aftern = 1,491
- Beforen = 897reference
- Outcome
- Hospital length of stay (LoS) and duration of intensive care stay
Methodological detailsmulticentre, 28 sites in 7 European countries
- Multicentre
- 28 sites in 7 European countries
Main finding
As reported in the abstract
Mean length of stay (LoS), before vs after BENCHMARK implementation (days)
7.7 ± 7.0 vs 5.8 ± 5.6
Median LoS, before vs after (days)
6 vs. 4
P < .001
Duration of intensive care, before vs after (days)
1.8 vs 1.3
Median intensive care duration, before vs after (days)
1.1 vs. 0.9
P < .001
Secondary outcomes
Use of local anaesthesia
- Increased use of local anaesthesia after vs before implementation
- 96.1% vs. 84.3%; P < .001
Procedure and intervention times
- Median procedure time, after vs before (min)
- 47 vs. 60; P < .001
- Intervention time, after vs before (min)
- 85 vs. 95; P < .001
Safety
30-day safety (both groups combined)
- No differences between groups; all-cause mortality
- 0.6%
- Stroke/TIA
- 1.4%
- Life-threatening bleeding
- 1.3%
- Stage 2/3 AKI
- 0.7%
- Valve-related readmission
- 1.2%
- Rates for both groups combined
Original publication
A streamlined pathway for transcatheter aortic valve implantation: the BENCHMARK study. Eur Heart J. Published 30 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →